Harvard Bioscience Management

Management Kriterienprüfungen 2/4

Harvard Bioscience CEO ist Jim Green , ernannt in Jul 2019, hat eine Amtszeit von 5.33 Jahren. Die jährliche Gesamtvergütung beträgt $2.39M , bestehend aus 24.5% Gehalt und 75.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 4.38% der Aktien des Unternehmens, im Wert von $4.56M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2 Jahre bzw. 7.1 Jahre.

Wichtige Informationen

Jim Green

Geschäftsführender

US$2.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts24.5%
Amtszeit als Geschäftsführer5.3yrs
Eigentum des Geschäftsführers4.4%
Durchschnittliche Amtszeit des Managements2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder7.1yrs

Jüngste Management Updates

Recent updates

Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Nov 07
Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Aug 07
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Jul 15
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10
Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Jun 08
Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Mar 15

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Feb 16
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Nov 04
Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

Oct 01
Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19
These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04
Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20
Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07
What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17
Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jim Green im Vergleich zu den Einnahmen von Harvard Bioscience verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$14m

Jun 30 2024n/an/a

-US$11m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$2mUS$586k

-US$3m

Sep 30 2023n/an/a

-US$3m

Jun 30 2023n/an/a

-US$5m

Mar 31 2023n/an/a

-US$2m

Dec 31 2022US$2mUS$574k

-US$10m

Sep 30 2022n/an/a

-US$7m

Jun 30 2022n/an/a

-US$4m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$3mUS$574k

-US$288k

Sep 30 2021n/an/a

-US$2m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$4m

Dec 31 2020US$3mUS$574k

-US$8m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$3mUS$265k

-US$5m

Sep 30 2019n/an/a

-US$2m

Jun 30 2019n/an/a

US$432k

Mar 31 2019n/an/a

-US$819k

Dec 31 2018US$153kn/a

-US$4m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$7m

Dec 31 2017US$129kn/a

-US$2m

Vergütung im Vergleich zum Markt: JimDie Gesamtvergütung ($USD2.39M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD651.15K).

Entschädigung vs. Einkommen: JimDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.


Geschäftsführer

Jim Green (66 yo)

5.3yrs

Amtszeit

US$2,392,240

Vergütung

Mr. James W. Green, also known as Jim, has been the Chairman of Harvard Bioscience, Inc. since June 5, 2017 and its Director since April 30, 2015. He serves as President and Chief Executive Officer of Harv...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
James Green
President5.3yrsUS$2.39m4.38%
$ 4.6m
Jennifer Cote
CFO & Treasurer1.8yrsUS$571.27k0.097%
$ 100.7k
John Fry
Chief Legal Counsel & Corporation Secretary2.3yrskeine Datenkeine Daten
Ryan Wallace
Senior Vice President of Global Sales1.5yrskeine Datenkeine Daten
Lori Packer
Vice President of Global People Operationsno datakeine Datenkeine Daten
Kathryn Flynn
Corporate Controllerno datakeine Datenkeine Daten
David Sirois
Director of Corporate Accounting & SEC Reportingno datakeine Datenkeine Daten

2.0yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrenes Management: HBIODas Führungsteam des Unternehmens gilt als erfahren (2 Jahre durchschnittliche Betriebszugehörigkeit).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
James Green
President9.6yrsUS$2.39m4.38%
$ 4.6m
Alan Edrick
Independent Director5.2yrsUS$213.09k0.52%
$ 545.0k
Bertrand Loy
Lead Independent Director10yrsUS$223.06k1.15%
$ 1.2m
Thomas Loewald
Independent Director7.1yrsUS$205.45k0.57%
$ 596.2k
Katherine Eade
Independent Director7.1yrsUS$198.09k0.61%
$ 634.0k

7.1yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: HBIODie Vorstandsmitglieder gelten als erfahren (7.1 Jahre durchschnittliche Amtszeit).